Lakefront Biotherapeutics reported EUR3.25B in Equity Capital and Reserves for its fiscal quarter ending in March of 2026.





Equity Capital And Reserves Change Date
argenx SE USD 8.42B 1.09B Jun/2026
AstraZeneca USD 50.3B 2.96B Jun/2026
Biogen USD 18.85B 196.3M Jun/2026
Genmab DKK 5.85B 96M Dec/2025
Gilead Sciences USD 11.74B 11.77B Jun/2026
GlaxoSmithKline GBP 17.64B 223M Jun/2026
GRIFOLS EUR 7.98B 2.52B Jun/2026
Hikma Pharmaceutical USD 2.59B 42M Dec/2025
Incyte USD 6.34B 721.58M Jun/2026
Merck EUR 29.74B 1.15B Mar/2026
Neurocrine Biosciences USD 3.69B 286.2M Jun/2026
Novartis USD 41.95B 3.02B Jun/2026
Roche Holding CHF 32.69B 1.11B Jun/2026
Sanofi EUR 69.57B 3.24B Jun/2026
UCB EUR 10.87B 1.18B Dec/2025
Vertex Pharmaceuticals USD 20.25B 886M Jun/2026